The IL1A gene encodes Interleukin-1 alpha¹¹ Interleukin-1 alpha
IL-1α is a pro-inflammatory cytokine released primarily from stressed or damaged cells; it binds the IL-1 receptor (IL-1R1) to activate NF-κB and drive inflammatory gene expression throughout the body, one of the body's most potent alarm signals for tissue damage. In endometriosis, IL-1α plays a central pathological role: it promotes adhesion of ectopic endometrial fragments to the peritoneal surface, stimulates blood vessel formation to nourish nascent implants, and activates tissue-remodeling enzymes that allow ectopic tissue to invade surrounding structures. rs3783550 is an intronic variant within IL1A that was identified as part of the first genome-wide significant evidence connecting the IL-1 inflammatory axis to endometriosis susceptibility.

The Mechanism

rs3783550 sits at chromosome 2, position 112,775,308 (GRCh38), within an intron of IL1A — specifically 41 base pairs before a splice junction (c.616-41 in coding-strand notation). Because IL1A is encoded on the minus strand of chromosome 2, the plus-strand alleles G and T correspond to C and A on the coding strand. The variant does not alter the IL-1α protein sequence. Its intronic location suggests it may act as a regulatory element²² regulatory element
Intronic variants can influence gene expression through effects on splicing efficiency, intronic enhancers, or long-range chromatin interactions with the gene promoter that modulates how much IL-1α is produced in response to inflammatory signals such as retrograde menstruation.

IL-1α operates through a well-characterized cascade: upon cell stress, pre-IL-1α is released and binds IL-1R1, triggering NF-κB-mediated transcription of downstream inflammatory mediators including IL-6, IL-8, VEGF (vascular endothelial growth factor), and matrix metalloproteinases. In the peritoneal cavity of women with endometriosis, elevated IL-1α promotes endometrial stromal cell survival on mesothelial surfaces, vascularization of new implants, and the fibrous adhesions characteristic of stage III/IV disease. A variant that amplifies IL1A expression — even modestly — would be expected to tip the peritoneal environment toward ectopic tissue establishment.

Recent work identifying M2 macrophages as major mediators of germline endometriosis risk³³ M2 macrophages as major mediators of germline endometriosis risk
Ochoa et al. 2025 Advanced Science; integrated data from 450,000 individuals and 350,000 single-cell transcriptomes across 21 patients placed IL1 signaling at the center of genetic susceptibility — and specifically showed that expression of IL1A is regulated by risk variants at this locus, providing functional support for the GWAS signal.

The Evidence

rs3783550 was characterized as part of a meta-analysis of 3,908 endometriosis cases and 8,568 controls⁴⁴ meta-analysis of 3,908 endometriosis cases and 8,568 controls
Sapkota et al. Association between endometriosis and the interleukin 1A (IL1A) locus. Human Reproduction, 2015 combining European and Japanese cohorts. Among eight IL1A locus SNPs tested, rs3783550 was one of three that showed nominal association with endometriosis in an independent Japanese sample (p < 0.05) and one of eight that successfully replicated in European imputed data (p < 0.014 with concordant direction of effect). The lead SNP in this region, rs6542095, reached genome-wide significance (OR 1.21, 95% CI 1.13–1.29; p = 3.43 × 10⁻⁸) for moderate-to-severe endometriosis. rs3783550 is in linkage disequilibrium with rs6542095, tagging the same IL1A risk haplotype.

The biological plausibility of this locus is reinforced by multiple lines of evidence. IL-1 receptor knockout and IRAK4 inhibition significantly reduced endometriotic lesion volume and Ki-67 expression in mouse models⁵⁵ IL-1 receptor knockout and IRAK4 inhibition significantly reduced endometriotic lesion volume and Ki-67 expression in mouse models
Kato et al. 2019 Frontiers in Immunology, demonstrating that IL-1 signaling causally drives lesion growth rather than being a secondary marker of inflammation. IL-1 receptor antagonist anakinra dampened pain and pro-angiogenic signaling in endometriosis-affected mice⁶⁶ IL-1 receptor antagonist anakinra dampened pain and pro-angiogenic signaling in endometriosis-affected mice
Ochoa et al. 2025, and an early clinical study showed peritoneal IL-1 concentrations sufficient to impair embryo development were present specifically in endometriosis patients⁷⁷ were present specifically in endometriosis patients
Fakih et al. 1987 Fertility and Sterility.

The evidence is classified as moderate — robust GWAS replication across two ancestries, clear biological mechanism, but individual per-SNP effect sizes for rs3783550 are not reported separately from the broader locus signal.

Practical Actions

The G allele at rs3783550 tags the IL1A endometriosis risk haplotype. Carrying G alleles does not diagnose endometriosis — it is one of many genetic contributors to a polygenic, hormonally and immunologically complex condition. The actionable implication is heightened alertness to symptoms that suggest moderate-to-severe (stage III/IV) disease, which is where the IL-1α-driven inflammatory pathology is most prominent: peritoneal adhesions, ovarian endometriomas, and deep infiltrating lesions.

Because the IL-1 pathway is the mechanistic link here, approaches that modulate peritoneal inflammation — including progestin-based hormonal suppression and timely laparoscopic excision of established lesions — directly target the biology implicated by this variant.

Interactions

rs6542095 (IL1A): rs3783550 is in linkage disequilibrium with rs6542095, the lead IL1A locus SNP associated with endometriosis at genome-wide significance. Together they tag the same IL1A risk haplotype; carrying risk alleles at both is consistent with inheritance of the same high-IL-1α regulatory block rather than two independent effects.

IL1B rs1143634 and IL1RN rs2234663: The IL-1 signaling axis involves both IL-1α (IL1A) and IL-1β (IL1B), which share the same receptor (IL-1R1) and act synergistically. The natural counter-regulator, IL-1 receptor antagonist (encoded by IL1RN), competitively inhibits both. Women carrying IL1A G-alleles alongside high-producing IL1B variants or low-producing IL1RN variants may experience amplified net peritoneal IL-1 signaling — a compounded inflammatory environment potentially more permissive to ectopic tissue establishment than any single variant alone.

Protein S, encoded by the PROS1 gene on chromosome 3, is a vitamin K-dependent¹¹ vitamin K-dependent
Protein S requires vitamin K for gamma-carboxylation of its Gla domain — a post-translational modification essential for membrane binding and anticoagulant function plasma glycoprotein that acts as a cofactor for activated protein C (APC) and tissue factor pathway inhibitor (TFPI). Together these brake the coagulation cascade — specifically disabling factors Va and VIIIa. When protein S is deficient, these brakes fail, and the blood is biased toward clotting. The R355C variant (rs387906674) causes hereditary protein S deficiency and was first linked to an unusually severe stroke phenotype in a three-generation Chinese family²² three-generation Chinese family
Six of eleven family members carried the mutation; all adult carriers showed white matter infarctions on MRI, while none of the noncarriers did.

The Mechanism

The PROS1 gene sits on the minus strand of chromosome 3 and encodes a 676-amino-acid mature protein with distinct structural domains: an N-terminal Gla domain, a thrombin-sensitive region, four EGF-like repeats, and a C-terminal sex hormone binding globulin (SHBG)-like region composed of two laminin G-like domains (LG1 and LG2). Arginine 355 sits in the LG1 domain — the very region that mediates TFPI cofactor activity and is competitively regulated by C4b-binding protein (C4BP). The LG1 domain contains critical residues for TFPI-alpha interaction³³ LG1 domain contains critical residues for TFPI-alpha interaction
Protein S LG1 is required for TFPI cofactor function; C4BP binding to LG1 almost completely abolishes this activity — a competitive mechanism that reduces functional free protein S.

The substitution of arginine (positively charged, large) for cysteine (small, can form aberrant disulfide bonds) at position 355 disrupts the local fold of LG1. Laboratory studies in affected carriers showed protein S deficiency type III⁴⁴ protein S deficiency type III
Type III: total protein S normal, but free protein S and functional activity are reduced — the most diagnostically challenging subtype because a standard total protein S test will appear normal: total plasma protein S levels are normal, but free protein S levels and APC-cofactor activity are reduced. This reflects impaired secretion or altered C4BP binding rather than reduced gene transcription.

The Evidence

The R355C variant was first reported by Leung et al. in Neurology (2010)⁵⁵ Leung et al. in Neurology (2010)
Leung TW et al. Genetic predisposition of white matter infarction with protein S deficiency and R355C mutation. Neurology. 2010;75(24):2156–63 in a Chinese family where haplotype analysis mapped the defect to a 6.1-Mb region on chromosome 3q11.2 (lod = 3.0). All adult R355C carriers showed deep white matter infarctions in borderzone regions on MRI — territory supplied by the distal ends of penetrating arteries and particularly vulnerable to hypoperfusion or microembolic occlusion. Strikingly, none of ten additional protein S deficiency families lacking this specific mutation showed cerebral infarction, raising the possibility that R355C impairs protein S function in the cerebral vasculature through a mechanism beyond simple quantitative deficiency.

In the broader context of PROS1 pathogenic variants, Ten Kate et al. in Human Mutation (2008)⁶⁶ Ten Kate et al. in Human Mutation (2008)
Analysis of 87 pedigrees across two phenotypic types found that type I protein S deficiency (low total and free PS) is overwhelmingly monogenic — PROS1 mutations identified in 34 of 35 probands — while type III (normal total, low free PS) is genetically heterogeneous. However, Castoldi et al. in Haematologica (2010)⁷⁷ Castoldi et al. in Haematologica (2010)
242 individuals from 30 families, 132 genetically characterized demonstrated that type I and type III deficiencies confer similar hypercoagulable states and equivalent thrombosis-free survival when assessed together in mixed-type families, arguing against dismissing type III as low-risk.

Among Chinese VTE patients, Wu et al. (2022)⁸⁸ Wu et al. (2022)
603 VTE patients and 584 matched controls; Frontiers in Cardiovascular Medicine quantified an odds ratio of 8.1 (95% CI 3.6–19.9) for VTE in individuals with protein S deficiency, with 43% of PROS1 coding-variant carriers experiencing VTE in their lifetime.

The variant is extremely rare globally — gnomAD v4 identifies only 6 alternate alleles across 1.4 million chromosomes sampled, with the highest frequency in East Asian populations (~0.008%). No homozygotes have been reported in population databases.

Practical Implications

Carriers of R355C should pursue functional free protein S assay⁹⁹ functional free protein S assay
Total protein S ELISA will appear normal in type III deficiency — only the free fraction and activity assays reveal the defect; testing ideally deferred 4+ weeks after an acute thrombotic event or VKA therapy testing to confirm the phenotype and establish a baseline. Because total protein S levels are normal, this deficiency is frequently missed on routine coagulation panels.

Oral contraceptives containing estrogen independently reduce protein S levels by 20–30% through effects on hepatic synthesis, potentially unmasking or compounding the existing deficiency in heterozygous carriers. Pregnancy produces a physiological drop in free protein S that is already hazardous in protein S-deficient women. Anticoagulation decisions following a thrombotic event should account for the additional hereditary component: most guidelines recommend extended anticoagulation (beyond 3 months) after an unprovoked VTE in carriers of high-risk thrombophilia variants.

Interactions

The most important interactions are with other inherited thrombophilias. Compound heterozygosity with Factor V Leiden (rs6025, FV R506Q)¹⁰¹⁰ Factor V Leiden (rs6025, FV R506Q)
The most common inherited thrombophilia in Europeans, present in 5%; double heterozygosity with any high-risk thrombophilia dramatically compounds VTE risk or with the prothrombin G20210A variant (rs1799963, F2)¹¹¹¹ prothrombin G20210A variant (rs1799963, F2)
G20210A raises prothrombin levels 30% and is found in 1–3% of Europeans; both variants impair anticoagulation through independent mechanisms would place a carrier at very high thrombotic risk. Acquired protein S reductions — from liver disease, antiphospholipid syndrome, nephrotic syndrome, or inflammatory states — further lower the functional protein S baseline already reduced by R355C.

Every day, your kidneys filter roughly 7–8 grams of uric acid from your blood. Almost all of it — about 90% — is immediately reabsorbed back into circulation, with just 10% making it into the urine. The protein responsible for most of this reabsorption is URAT1¹¹ URAT1
Urate transporter 1 — an antiporter on the apical membrane of proximal tubule cells; it imports urate into the tubule cell in exchange for organic anions (lactate, nicotinate, pyrazinoate), effectively rescuing urate from the filtrate before it reaches the collecting duct, encoded by SLC22A12. The rs475688 variant sits deep in an intron of this gene, where it acts as an expression switch: the T allele turns URAT1 expression up, producing more transporter protein on the tubule surface and reabsorbing more urate with every liter of filtrate.

The Mechanism

Unlike missense variants that change the URAT1 protein's function, rs475688 changes how much URAT1 is made. A 2025 study in the Journal of Clinical Investigation established rs475688 as a kidney eQTL²² kidney eQTL
expression quantitative trait locus — a genetic variant that alters how strongly a nearby gene is expressed in a specific tissue, measurable by comparing mRNA levels across genotypes in that tissue for SLC22A12 in the renal proximal tubule. Each copy of the T allele adds a measurable increment to SLC22A12 mRNA levels, which translates directly to more URAT1 protein at the tubule surface, higher fractional urate reabsorption, and a raised serum urate setpoint.

The same study revealed an important gene-environment interaction: T carriers show a synergistically amplified urate response to hyperinsulinemia³³ hyperinsulinemia
chronically elevated blood insulin levels, typically seen in insulin resistance, metabolic syndrome, and early type 2 diabetes; insulin independently stimulates URAT1 activity via AKT-mediated phosphorylation of URAT1-Thr408, an effect compounded when more URAT1 protein is available. This means high-carbohydrate diets and insulin resistance can interact multiplicatively with rs475688 to push urate levels well above what either factor would cause alone.

High fructose intake deserves separate mention: fructose metabolism consumes ATP rapidly (generating AMP → IMP → hypoxanthine → xanthine → urate), producing a urate surge that is then retained more efficiently in T allele carriers because URAT1 has a lower renal urate excretion efficiency.

The Evidence

The T allele's effect on urate was quantified at scale in 377,358 UK Biobank participants⁴⁴ 377,358 UK Biobank participants
Hosoyamachi S et al. Gene-environment interaction modifies the association between hyperinsulinemia and serum urate levels through SLC22A12. J Clin Invest, 2025: serum urate rose by 3.58 µmol/L per T allele copy (P = 4.54 × 10⁻⁸⁰), with CC individuals averaging 306.7 µmol/L, CT averaging 309.7 µmol/L, and TT averaging 313.3 µmol/L. This 6.6 µmol/L step from CC to TT is clinically meaningful at the tipping point near the urate supersaturation threshold⁵⁵ supersaturation threshold
Urate becomes sparingly soluble in plasma at approximately 408 µmol/L (6.8 mg/dL) — above this concentration, monosodium urate crystals can nucleate and deposit in joints, tendons, and soft tissues, triggering gout of ~408 µmol/L (6.8 mg/dL).

A meta-analysis of 7 studies⁶⁶ meta-analysis of 7 studies
Zou B et al. Associations between the SLC22A12 gene and gout susceptibility: a meta-analysis. Clin Rheumatol, 2018 (1,216 gout cases, 1,844 controls) found that having at least one risk allele compared to the low-risk homozygote was associated with OR = 2.03 (95% CI 1.49-2.76) for gout. A separate Japanese case-control study⁷⁷ Japanese case-control study
Nakayama A et al. Additive composite ABCG2, SLC2A9 and SLC22A12 scores of high-risk alleles with alcohol use modulate gout risk. J Hum Genet, 2016 found that the SLC22A12 risk allele independently predicted gout with OR 1.95 per allele copy, and that risk alleles across ABCG2, SLC2A9, and SLC22A12 compounded in additive fashion — particularly in heavy drinkers, where alcohol metabolism drives both purine production and lactate-mediated URAT1 stimulation.

Population variation in rs475688 is striking: in European and African populations the T allele runs at ~26-32%, while in East Asian populations (Japanese, Korean, Vietnamese) T approaches 50% or higher — the population with the highest gout prevalence globally⁸⁸ highest gout prevalence globally
Gout affects 3-4% of adults in many East Asian countries, compared to 2-3% in Western populations, with male-predominant hyperuricemia rates of 10-30% in Korea and Japan; this excess is multifactorial but URAT1 genetics likely contribute.

Practical Actions

For TT individuals, the urate setpoint is measurably higher and the kidney is working against any dietary effort to lower urate. The most effective strategy is reducing urate production (limit high-purine foods and fructose) while also reducing the competing organic anion substrates that URAT1 uses to cotransport urate (lactate from alcohol, nicotinate from certain supplements). If serum urate is persistently above 6.0 mg/dL despite dietary changes, uricosuric medications — which directly inhibit URAT1 — are the mechanistically appropriate drug class for this genotype.

For CT individuals, the same directional advice applies at lower urgency. Serum urate monitoring and preemptive dietary attention to fructose and purine load are appropriate.

Interactions

The rs475688 interaction with SLC2A9 (rs1079128, rs11942223) is additive: individuals who carry T alleles at both loci have URAT1 overexpression AND GLUT9 overexpression — two complementary reabsorption mechanisms both running hot. ABCG2 (rs2231142) is a urate efflux transporter on the intestinal epithelium; ABCG2 dysfunction and URAT1 overexpression combine to raise serum urate from both ends (reduced gut secretion and increased renal reabsorption).

The insulin-URAT1 pathway (via AKT phosphorylation of URAT1-Thr408) means that metabolic syndrome and insulin resistance are particularly hazardous for T allele carriers — managing blood sugar helps manage urate.

Aromatase is the enzyme that converts androgens (testosterone, androstenedione) into estrogens (estradiol, estrone). Without it, no estrogen is made. The CYP19A1 gene encodes aromatase and is expressed in multiple tissues — ovaries, bone, breast, brain, and adipose. rs4775936, located in a negative regulatory region¹¹ negative regulatory region
a promoter region that normally suppresses gene transcription of CYP19A1 (specifically exon I.6), influences how much aromatase is made in those tissues. Even modest changes in aromatase activity reshape the androgen-to-estrogen ratio across the body, with downstream effects on bone density, fertility, breast tissue, and how well aromatase-blocking drugs work.

The Mechanism

CYP19A1 is expressed from multiple tissue-specific promoters. The rs4775936 variant sits within the I.6 promoter region — a regulatory element that governs aromatase expression in bone and gonadal tissue. CYP19A1 lies on the minus strand of chromosome 15; the variant is C→T on the genomic plus strand (corresponding to G→A on the coding strand, which is why older papers describe it as an A/G polymorphism). The T allele appears to alter binding affinity for transcriptional repressors, modifying aromatase output in a tissue-specific manner. This promoter-level regulation — rather than a change in the aromatase protein itself — explains why the variant's effects are context-dependent, varying by tissue type, sex, age, and hormonal environment.

The Evidence

Bone mineral density. Enjuanes et al. studied 256 postmenopausal Spanish women²² Enjuanes et al. studied 256 postmenopausal Spanish women
Enjuanes A et al. A new SNP in a negative regulatory region of the CYP19A1 gene is associated with lumbar spine BMD in postmenopausal women. Bone, 2006 and found that TT homozygotes had significantly higher lumbar spine bone mineral density compared to CC or CT individuals (p=0.029). Higher local aromatase activity in bone increases estradiol at the tissue level, which suppresses osteoclast-driven bone resorption — the likely mechanism.

Aromatase inhibitor response. Park et al. genotyped 46 CYP19A1 variants in 109 patients with hormone receptor-positive metastatic breast cancer on letrozole³³ Park et al. genotyped 46 CYP19A1 variants in 109 patients with hormone receptor-positive metastatic breast cancer on letrozole
Park IH et al. Single nucleotide polymorphisms of CYP19A1 predict clinical outcomes associated with letrozole. Cancer Chemother Pharmacol, 2011. The T allele of rs4775936 was associated with higher clinical benefit rate (OR 2.60, 95% CI 1.12–6.02, p=0.026). A larger retrospective study of 308 patients by Ferraldeschi et al. confirmed a trend⁴⁴ Ferraldeschi et al. confirmed a trend
Ferraldeschi R et al. Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer. Breast Cancer Res Treat, 2012 (HR 0.79 per T allele, 95% CI 0.66–0.95, p=0.012), though the effect was attenuated after adjusting for disease extent and other prognostic factors.

Aromatase inhibitor-induced arthralgia. Borrie et al. prospectively followed 196 women initiating letrozole or anastrozole⁵⁵ Borrie et al. prospectively followed 196 women initiating letrozole or anastrozole
Borrie AE et al. Genetic and clinical predictors of arthralgia during letrozole or anastrozole therapy. Breast Cancer Res Treat, 2020. More than 50% of the group experienced arthralgia, and rs4775936 was significantly associated with both developing arthralgia (adjusted p=0.016) and with discontinuing therapy due to intolerable joint pain. The same variant that may improve tumor response appears also to predispose to this debilitating side effect — likely through altered estrogen withdrawal kinetics in joint tissue.

Lipid effects. In 303 women on adjuvant aromatase inhibitors, Santa-Maria et al. identified rs4775936 as one of seven CYP19A1 variants linked to triglyceride reductions of 20.2–39.3 mg/dL⁶⁶ Santa-Maria et al. identified rs4775936 as one of seven CYP19A1 variants linked to triglyceride reductions of 20.2–39.3 mg/dL
Santa-Maria CA et al. Association of variants in candidate genes with lipid profiles in women on adjuvant aromatase inhibitor therapy. Clin Cancer Res, 2016 (p<0.00053), reflecting aromatase's role in modulating sex-hormone-sensitive lipid metabolism.

Cancer risk. A meta-analysis of 25,446 endometrial cancer cases and 41,106 controls found CYP19A1 rs4775936 associated with increased endometrial cancer risk⁷⁷ CYP19A1 rs4775936 associated with increased endometrial cancer risk
Das AP et al. Meta-analysis of 49 SNPs identifies polymorphisms in hormone regulation genes associated with endometrial cancer risk. Genes, 2023. In prostate cancer, Kanda et al. reported⁸⁸ Kanda et al. reported
Kanda S et al. Functional genetic polymorphisms in CYP19A1 and prostate cancer risk and survival. Int J Cancer, 2015 that the variant allele reduced prostate cancer susceptibility but correlated with shorter survival in metastatic disease — possibly through effects on the estrone/androstenedione ratio in the tumor microenvironment.

Practical Actions

People carrying one or two T alleles face a nuanced picture: potential protection in bone density, possible benefit in aromatase inhibitor treatment response, but elevated risk of AI-induced joint pain and need for proactive monitoring of hormone-sensitive tissue (endometrium, prostate). Given that this variant acts through tissue-specific promoter modulation, the downstream effects depend heavily on hormonal context — most pronounced in postmenopausal women (low circulating estrogens, maximal dependence on local aromatase) and during AI therapy (aromatase pharmacologically suppressed).

Women with breast cancer being considered for aromatase inhibitor therapy should ensure their oncology team is aware of this variant: it may inform both expected response and the likelihood of joint-pain-driven discontinuation. For postmenopausal women not on AI therapy, higher local aromatase activity in bone may confer modest skeletal protection — though this requires adequate calcium and vitamin D to be realized.

Interactions

rs4775936 sits within a CYP19A1 haplotype block with several other functional variants, including rs10046, rs700518, rs1062033, and rs767199. Combined haplotype analyses consistently show stronger associations than any single SNP alone, particularly for bone density and hormone levels. The variant also interacts with estrogen receptor alpha variants (ESR1) — ESR1 polymorphisms modulate sensitivity to aromatase-derived estrogens, so the combination of altered aromatase output (CYP19A1) and altered estrogen signaling (ESR1) can amplify or dampen phenotypic effects. Gene-environment interactions with fracture risk probability scores have been documented (PMID 41929826), suggesting clinical context mediates genetic risk substantially.

BLK (B-lymphoid tyrosine kinase)¹¹ BLK (B-lymphoid tyrosine kinase)
A Src-family non-receptor tyrosine kinase expressed almost exclusively in B cells and plasmacytoid dendritic cells is a critical regulator of B-cell receptor signaling and B-cell tolerance. rs4840568 is a 2kb-upstream variant in the same FAM167A-BLK regulatory region as the more extensively studied rs13277113, and the two variants sit roughly 1.8 kilobases apart on chromosome 8p23.1. Multiple studies have genotyped both SNPs simultaneously; in Han Chinese populations they are in strong linkage disequilibrium²² strong linkage disequilibrium
LD r²>0.9 and D′>0.9, meaning the two alleles are nearly always inherited together in East Asian populations, per Yin et al. 2021 (PMID 34637583). Despite this LD, rs4840568 shows somewhat different allele frequencies across ancestries — particularly a higher A-allele frequency in African and Latino populations than rs13277113 — suggesting it may tag additional regulatory variation or capture LD with functional elements that rs13277113 does not fully represent in non-Asian populations.

The Mechanism

Like rs13277113, rs4840568 sits in the shared promoter/enhancer region upstream of the BLK transcription start site. Variants in this region collectively modulate BLK mRNA levels in B cells: the risk haplotype carrying A alleles at both rs4840568 and rs13277113 is associated with lower BLK expression in B-cell lines, measured directly in the 2008 discovery study³³ 2008 discovery study
Hom et al. 2008 — BLK mRNA reduced in B-cell lines from carriers of the risk haplotype. Reduced BLK kinase activity impairs the tolerance checkpoint that normally eliminates self-reactive B-cell clones in the bone marrow, allowing autoreactive B cells to survive and produce autoantibodies — the molecular driver of SLE, Sjögren's syndrome, and related diseases.

Whether rs4840568 has independent functional effects beyond tagging the rs13277113 risk haplotype has not been resolved in functional studies. The 2021 NMOSD study⁴⁴ 2021 NMOSD study
Yin et al. — 310 Han Chinese individuals; rs4840568 showed no independent association with neuromyelitis optica after haplotype conditioning found no independent rs4840568 signal after accounting for the broader haplotype. Nevertheless, the variant independently appeared in a multi-phenotype GWAS⁵⁵ multi-phenotype GWAS
Sakaue et al. 2021 — largest multi-trait GWAS to date, combining data across thousands of traits as a genome-wide significant hit for serum total protein levels (beta=+0.028, P=4×10⁻³³), consistent with altered immunoglobulin and immune protein output in risk-allele carriers.

The Evidence

The primary evidence anchor is the Zeng et al. 2017 meta-analysis⁶⁶ Zeng et al. 2017 meta-analysis
PMID 28885337 — 33 studies total; rs4840568 analysis covered 4 studies with 11,391 SLE cases and 10,972 controls, which found rs4840568 A allele OR=1.32 (95% CI 1.22–1.43) for SLE, comparable to the rs13277113 OR of 1.33 in the same paper. An earlier Chinese case-control study⁷⁷ Chinese case-control study
Chen et al. 2012 — 532 SLE cases, 576 controls; high-resolution melting genotyping found significant allele associations for both rs4840568 and rs13277113 in a Han Chinese cohort.

Beyond SLE, a Chinese AITD cohort⁸⁸ Chinese AITD cohort
Song et al. 2018 — 999 autoimmune thyroid disease patients (624 Graves' disease, 375 Hashimoto's thyroiditis) and 797 controls; adolescent-focused analysis found the A allele of rs4840568 linked to autoimmune thyroid disease susceptibility, extending the BLK locus associations beyond the traditional SLE/RA/Sjögren's disease spectrum.

The evidence base for rs4840568 specifically is thinner than for rs13277113 — four studies versus twenty-four — and the independence of the rs4840568 signal from the rs13277113 haplotype has not been established. Given the strong LD between the two variants in Asian populations, the practical clinical implication is similar: elevated background risk for B-cell-driven autoimmune disease, with monitoring as the primary action.

Practical Implications

Carriers of the A allele at rs4840568 are likely also carrying the A allele at rs13277113 in the same chromosomal segment, particularly if they are of Asian ancestry. The combined risk profile of the BLK locus — elevated in individuals with A alleles at multiple BLK region SNPs — centers on a modestly increased lifetime risk for systemic lupus erythematosus, and potentially for autoimmune thyroid disease (Graves' disease and Hashimoto's thyroiditis). These are treatable conditions with excellent outcomes when detected early.

There are no proven dietary supplements or pharmacological preventions for BLK-mediated autoimmune predisposition. The actionable response is symptom awareness and access to appropriate screening.

Interactions

rs4840568 and rs13277113 are in strong LD (r²>0.9 in East Asian populations) and are likely co-inherited as part of the same BLK risk haplotype in most individuals. Their combined presence on a single chromosome is the unit of risk rather than independent additive contributions. The broader BLK-BANK1 interaction documented for rs13277113 is expected to apply equally to rs4840568 carriers, since the same haplotype block is implicated in both studies.

For individuals with rs4840568 AA genotype who also carry risk alleles at BANK1 rs10516487⁹⁹ BANK1 rs10516487
BANK1 R61H variant in B-cell scaffold protein; synergistic with BLK variants for Sjögren's syndrome risk (OR=2.36 combined), the combined risk for primary Sjögren's syndrome is substantially elevated beyond either variant alone.

Alpha-adducin is a cytoskeletal protein that does something quietly consequential in your kidney tubules: it controls how many sodium pumps sit active at the cell surface. The ADD1 gene (adducin 1)¹¹ ADD1 gene (adducin 1)
encodes the alpha subunit of the adducin heterotrimer, which links the spectrin-actin cytoskeleton to the plasma membrane and regulates ion transport channel trafficking in kidney cells. When adducin stabilizes the Na+/K+-ATPase²² Na+/K+-ATPase
the sodium-potassium pump that moves three sodium ions out of the cell for every two potassium ions in, establishing the electrochemical gradient that drives secondary sodium transport at the cell surface, more sodium gets reabsorbed from the tubular filtrate back into the bloodstream — raising blood volume and, with it, blood pressure.

The Gly460Trp variant substitutes tryptophan for glycine at position 460 in the protein's tail domain, altering how tightly the pump anchors. About 19% of Europeans carry at least one copy of the Trp allele; in East Asian populations the frequency climbs to 51%, which may partly explain higher rates of salt-sensitive hypertension in those populations.

The Mechanism

At position 460, the normal glycine (Gly) creates a flexible hinge in adducin's tail domain. Substituting tryptophan (Trp) — a bulkier, aromatic amino acid — rigidifies the structure and increases affinity for the Na+/K+-ATPase³³ increases affinity for the Na+/K+-ATPase
the Trp460 isoform stabilizes the pump at the apical membrane of renal proximal tubule cells, increasing its surface density and thus its total sodium transport capacity. More pumps at the surface means more tubular sodium reabsorption.

The consequence unfolds in two kidney compartments. In the proximal tubule, where most filtered sodium is reclaimed, Trp460 adducin increases baseline sodium reabsorption. When a salt load arrives — a salty meal, intravenous saline — the Trp460 kidney retains more of that sodium rather than excreting it, blunting the normal pressure-natriuresis response and causing a steeper, more prolonged blood pressure rise.

The Trp460 variant also impairs endothelial function. In the vasculature, adducin helps organize caveolae — the lipid-raft microdomains where endothelial nitric oxide synthase (eNOS) resides. Disruption of this organization reduces eNOS activation, blunting nitric oxide-dependent vasodilation and adding a vascular component to the hypertension risk.

The Evidence

The vascular consequences are documented in a study of 110 never-treated hypertensive patients⁴⁴ 110 never-treated hypertensive patients
Perticone et al., J Hypertens 2007. Trp allele carriers showed markedly impaired forearm blood flow response to acetylcholine — a test of endothelium-dependent vasodilation — rising only 269% at the highest dose versus 395% in Gly/Gly homozygotes (P<0.001). The response to sodium nitroprusside, which acts independently of the endothelium, was identical between groups, confirming that the deficit is specifically endothelial, not vascular smooth muscle.

Cardiovascular outcomes data come from the Rotterdam Study (6,471 participants)⁵⁵ Rotterdam Study (6,471 participants)
van Rijn et al., Stroke 2006, where Trp allele carriers had a stroke hazard ratio of 1.22 (95% CI 1.02–1.45), ischemic stroke HR 1.29 (95% CI 1.02–1.63), and myocardial infarction HR 1.33 (95% CI 1.05–1.69). Carotid intima-media thickness was modestly increased in carriers (0.80 vs 0.79 mm, P=0.04). Critically, the interaction between the Gly460Trp polymorphism and hypertension was statistically significant — the risk was amplified in those who were also hypertensive, linking the molecular sodium-retention mechanism to hard cardiovascular outcomes.

For pharmacogenomics, a meta-analysis of 4 studies (1,001 patients)⁶⁶ meta-analysis of 4 studies (1,001 patients)
Choi et al., Int J Clin Pharmacol Ther 2013 found that the GlyGly genotype achieved significantly greater blood pressure reduction on hydrochlorothiazide than TrpTrp homozygotes (standard difference 1.80, 95% CI 1.38–2.22). The sodium-retaining effect of Trp460 adducin partially offsets the diuretic's mechanism, which also targets tubular sodium transport.

A Ukrainian cohort study (2024)⁷⁷ Ukrainian cohort study (2024)
Sydorchuk et al., Endocr Regul confirmed that T-allele carriers in hypertensive patients had approximately 4-fold higher odds of being sodium-sensitive — women OR 4.71 (95% CI 1.92–11.56, P<0.001) and men OR 4.09 (95% CI 1.03–16.28, P=0.041).

Practical Actions

For Trp allele carriers — particularly TT homozygotes — the most actionable intervention is aggressive dietary sodium restriction. Unlike the general population, where blood pressure response to sodium reduction is variable, carriers of the Trp460 allele have a documented biological mechanism that makes sodium reduction disproportionately effective.

Hydrochlorothiazide, the most commonly prescribed first-line antihypertensive, works less well in Trp carriers because both the drug and adducin act on overlapping tubular sodium transport pathways. If hypertension requires pharmacotherapy, ACE inhibitors, ARBs, or renin-angiotensin-aldosterone system agents may be pharmacologically better matched to this genotype.

Monitoring endothelial function through blood pressure response tracking and periodic cardiovascular risk assessment is warranted for TT homozygotes, who face the combination of both renal sodium retention and impaired vasodilation.

Interactions

The ADD1 Trp460 allele functions as a permissive variant in the renal sodium handling network. A physiological interaction study involving ADD1 (rs4961), WNK1, and NEDD4L (rs1008899/rs4149601) found that the ADD1 Trp allele is required for the effects of the other variants to manifest — individuals carrying risk alleles at all three loci showed the most pronounced sodium retention, the highest blood pressure on saline loading (P=0.021), and the greatest response differential to thiazide therapy (P=0.008). This axis — ADD1 → WNK1 → NEDD4L → ENaC — represents a coherent sodium-retention pathway where each node amplifies the others' effects.

The interaction with endogenous ouabain (a naturally occurring Na+/K+-ATPase inhibitor circulating at low levels in plasma) is also documented: Trp460 carriers with elevated ouabain showed the largest blood pressure rises on volume loading, suggesting adducin-ouabain co-regulation of pump density.

The skin's outermost layer depends on a single protein — filaggrin — to hold it together, retain water, and keep allergens out. The FLG gene encodes profilaggrin¹¹ profilaggrin
a massive 435-kDa precursor protein that is proteolytically cleaved during terminal epidermal differentiation into 10–12 filaggrin monomers, which aggregate keratin filaments into the compact waterproof matrix of the stratum corneum. The 2282del4 variant (c.2282_2285del, deletion of four nucleotides in the coding sequence) shifts the reading frame at codon 762, generating a premature stop codon roughly 36 codons later — eliminating all downstream filaggrin repeats from that allele. This is the second most common FLG loss-of-function allele in European populations²² the second most common FLG loss-of-function allele in European populations
The most common is R501X (rs61816761), which together with 2282del4 accounts for approximately 90% of FLG null alleles in Europeans; their combined allele frequency is approximately 4% in this ancestry.

The Mechanism

2282del4 produces the same downstream consequence as R501X: haploinsufficiency of filaggrin protein when heterozygous, and complete filaggrin absence when combined with a second null allele. A single non-functional copy reduces total filaggrin output by approximately 50%, impairing the formation of natural moisturizing factor (NMF)³³ natural moisturizing factor (NMF)
a hygroscopic mixture of amino acids, urocanic acid, pyrrolidone carboxylic acid, urea, and ions — the metabolic breakdown products of filaggrin — that maintain stratum corneum hydration and the acidic pH (4.5–5.5) essential for normal barrier function. Without adequate NMF, transepidermal water loss (TEWL) increases, skin pH rises into the alkaline range, and structural gaps between corneocytes open — allowing environmental allergens (house dust mite, pollen, food proteins) to penetrate into the viable epidermis and trigger IgE sensitization through the skin rather than through the gut. This percutaneous sensitization pathway is the molecular basis of the atopic march⁴⁴ atopic march
the sequential progression from atopic eczema in infancy, to food allergy, to asthma, and allergic rhinitis — each step driven by IgE sensitization initiated through the defective skin barrier.

Inheritance is semidominant: heterozygotes have intermediate phenotype (often identifiable only by palmar hyperlinearity and subtle dryness), while homozygotes and compound heterozygotes show overt ichthyosis vulgaris⁵⁵ homozygotes and compound heterozygotes show overt ichthyosis vulgaris
fish-scale scaling most prominent on the legs and trunk, palmar hyperlinearity, keratosis pilaris; typically begins in early childhood and may improve in adulthood.

The Evidence

The 2282del4 mutation was identified in 2006 by Smith et al.⁶⁶ Smith et al.
Smith FJ et al. Loss-of-function mutations in the gene encoding filaggrin cause ichthyosis vulgaris. Nat Genet. 2006 as one of two primary causative mutations for ichthyosis vulgaris, and simultaneously by Palmer et al.⁷⁷ Palmer et al.
Palmer CN et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006 as a strong predisposing factor for atopic dermatitis. Heterozygous carriers show elevated eczema risk with effect sizes comparable to R501X; a meta-analysis of 24 studies⁸⁸ meta-analysis of 24 studies
Rodríguez et al. 2009 found overall odds ratio for eczema of 3.12 (95% CI 2.57–3.79) and for eczema-plus-asthma of 3.29 (95% CI 2.84–3.82) across FLG null alleles as a group. Asthma risk is substantially driven by the eczema-asthma compound phenotype: when eczema is absent, the FLG-asthma association disappears, confirming that skin barrier deficiency — not a direct pulmonary effect — is the primary mechanism.

The functional consequences of compound heterozygosity (one 2282del4 allele plus one R501X allele on the opposite chromosome) are equivalent to homozygosity for either mutation alone: all 37 R501X/2282del4 compound heterozygous individuals examined by Carlsen et al.⁹⁹ Carlsen et al.
Carlsen BC et al. Filaggrin compound heterozygous patients carry mutations in trans position. Exp Dermatol. 2013 carried their mutations in trans, establishing complete filaggrin deficiency. Thyssen et al.¹⁰¹⁰ Thyssen et al.
Thyssen JP et al. Individuals who are homozygous for 2282del4 and R501X filaggrin null mutations do not always develop dermatitis. J Eur Acad Dermatol Venereol. 2012 found that compound heterozygous/homozygous individuals represent 3% of all dermatitis patients but 0.3% of the general adult population, and that penetrance is incomplete — some do not develop clinical eczema, suggesting environmental and genetic modifiers influence the clinical expression of genetic barrier deficiency.

Among complications, FLG null alleles sharply elevate eczema herpeticum risk: the combined null genotype (carrying two null alleles) confers odds ratio of 10.1 (95% CI 4.7–22.1, P = 2×10⁻¹¹) for eczema herpeticum versus atopic dermatitis without this complication, compared to OR 3.4 for R501X heterozygosity alone.

Practical Actions

The actionable framework for 2282del4 parallels R501X, because the mechanism is identical: filaggrin haploinsufficiency creates a barrier that needs ongoing external support. Ceramide- dominant emollients (containing ceramide, cholesterol, and free fatty acids at the physiologic 3:1:1 ratio) compensate for impaired NMF production and barrier lipid assembly. Urea-containing formulations (5–25% depending on body region) are particularly suitable as urea is itself an NMF component and can upregulate residual FLG expression in skin cells. Fragrance, methylisothiazolinone, sodium lauryl sulfate, and propylene glycol at high concentrations disproportionately penetrate compromised barriers and should be eliminated from personal care routines.

For heterozygous carriers currently without eczema: proactive moisturizing during high-stress periods (low humidity, cold, frequent handwashing, chlorinated water) preserves barrier integrity before sensitization can establish. For parents carrying 2282del4: the evidence from the BEEP/LEAP framework¹¹¹¹ BEEP/LEAP framework
Early emollient use from birth reduces AD incidence by ~50% in high-risk infants (Simpson et al. 2014) and early oral introduction of allergenic foods (peanut, egg, fish) provides the highest-impact prevention window before percutaneous sensitization establishes food allergy.

Interactions

2282del4 (rs558269137) and R501X (rs61816761) are the two most common FLG null alleles in Europeans and interact as compound heterozygotes. When one copy of 2282del4 is carried on one chromosome and one copy of R501X on the other, the individual has no functional FLG allele at all — an outcome functionally identical to homozygosity for either mutation. This compound heterozygous state produces the full filaggrin-null phenotype: overt ichthyosis vulgaris, high-penetrance severe atopic dermatitis, dramatically elevated asthma risk, and the highest risk of eczema herpeticum of any single-locus FLG genotype. Because each mutation is relatively common in Europeans (each approximately 2% allele frequency), the compound heterozygous state occurs with meaningful frequency: roughly 1 in 2,500 Europeans. The clinical management of compound heterozygotes is identical to FLG homozygotes — intensive daily emollient therapy, dermatology referral, dupilumab consideration for moderate-to-severe eczema, and vigilance for eczema herpeticum.

Proposed compound action for supervisor: When a user carries rs558269137 with a D allele (DI or DD) AND rs61816761 with an A allele (AG or AA), they are compound heterozygous with complete filaggrin absence. The combined recommendation should address zero filaggrin production: intensive twice-daily ceramide-dominant emollient therapy, dermatology referral for personalized ichthyosis/eczema management, dupilumab evaluation if moderate-to-severe eczema, eczema herpeticum recognition and emergency response, and early allergen introduction in offspring. Evidence level: established.

Within the TMPRSS6 gene — the same gene that harbors the well-characterized Ala736Val variant (rs855791) — lies a cluster of common intronic polymorphisms that collectively fine-tune the activity of matriptase-2¹¹ matriptase-2
A type II transmembrane serine protease expressed in the liver that negatively regulates hepcidin, the master iron-regulatory hormone. The rs5756506 variant, located deep in intron 13 of TMPRSS6 approximately 320 bases upstream of the exon 14 splice acceptor, does not change any amino acid but appears to influence the overall iron-regulatory output of this gene at the population level.

TMPRSS6 encodes matriptase-2, whose primary job is to keep hepcidin²² hepcidin
A 25-amino-acid peptide hormone secreted by the liver that controls systemic iron homeostasis by blocking ferroportin, the only known iron exporter on gut and macrophage cell surfaces levels from rising too high. By cleaving hemojuvelin³³ hemojuvelin
A membrane-bound co-receptor that drives the BMP/SMAD signaling cascade responsible for hepcidin transcription off the liver cell surface, matriptase-2 acts as a natural brake on hepcidin production. When any variant — coding or non-coding — reduces the effective activity of this brake, hepcidin rises and iron absorption falls.

The Mechanism

rs5756506 is an intronic variant with no protein-level consequence. Intronic variants in this position can influence gene function through several mechanisms: altered splicing efficiency of the adjacent exon 14, modification of regulatory elements that affect transcription factor binding, or linkage disequilibrium with nearby functional variants. The variant falls within a 300-nucleotide intronic window upstream of the exon 14 splice acceptor (coding notation c.1556-320), a region where branch point sequences and polypyrimidine tracts critical for splicing fidelity are typically found.

The G allele at rs5756506 (GRCh38 plus-strand reference) is the common allele in European (~76%), South Asian (~95%), and East Asian (~97%) populations, while the C allele predominates in African populations (1000 Genomes: ~84% C in Africans). The C allele is associated with measurably higher hemoglobin and hematocrit in healthy individuals, consistent with enhanced matriptase-2 function — more efficient hepcidin suppression and therefore better iron absorption and utilization.

The Evidence

The primary association data comes from a Turkish candidate-gene study by Batar et al.⁴⁴ Batar et al.
Batar B et al. The role of TMPRSS6 gene variants in iron-related hematological parameters in Turkish patients with iron deficiency anemia. Gene, 2018, which genotyped eight TMPRSS6 SNPs in 150 IDA patients and 100 healthy controls. Among all variants examined, rs5756506 was the only one associated with hemoglobin (P=0.02) and hematocrit (P=0.03) specifically in the healthy control group, while no significant difference was observed between patients and controls. This pattern suggests the variant modulates baseline iron regulatory tone rather than directly determining susceptibility to iron deficiency anemia.

A population genetics analysis⁵⁵ population genetics analysis
Phelan D et al. Differences in the frequency of genetic variants associated with iron imbalance among global populations. PLoS ONE, 2020 identified rs5756506 among TMPRSS6 variants with population branch statistic values exceeding the top 5% genome-wide threshold (AFR PBS=0.25), indicating this locus has been subject to different selective pressures in African versus non-African populations. The high C allele frequency in Africans — a population historically exposed to endemic malaria, which causes hemolytic anemia — may reflect positive selection for enhanced iron absorption capacity.

In contrast, a study of 1,316 healthy Gambians⁶⁶ 1,316 healthy Gambians
Jallow MW et al. Association of common TMPRSS6 and TF gene variants with hepcidin and iron status in healthy rural Gambians. Sci Rep, 2021 found no independent association of rs5756506 with hepcidin, iron biomarkers, or hematological parameters. The null result in this West African cohort — where the C allele is common and most individuals are C allele carriers — may reflect reduced statistical power to detect heterozygous effects when homozygous CC is the population norm.

Practical Implications

The evidence for rs5756506 is emerging and limited to small or population-specific studies. Individuals homozygous for the G allele (GG) represent the common European genotype and may have modestly lower hemoglobin and hematocrit than C allele carriers under the same dietary conditions. This is particularly relevant when iron demands are elevated — during menstruation, pregnancy, endurance training, or on plant-based diets where non-heme iron bioavailability is inherently lower.

Monitoring ferritin and hemoglobin provides the clearest picture of actual iron status regardless of genotype. For GG individuals who already show borderline iron stores, dietary iron optimization — pairing iron-rich foods with vitamin C, choosing heme iron sources where possible, and avoiding absorption inhibitors like tea and coffee at meals — can partially compensate for any genetically reduced absorption capacity.

Interactions

rs5756506 is in low linkage disequilibrium with the primary TMPRSS6 functional variants rs855791 (Ala736Val) and rs4820268 in non-African populations, meaning the variants contribute relatively independently to iron regulation. rs2235321, another intronic TMPRSS6 variant, has been reported to independently affect hepcidin levels in Gambian adults. Together, these common TMPRSS6 variants may explain a portion of the genetic variance in iron status that is not captured by the rs855791 variant alone.

The interaction with HFE hemochromatosis variants (C282Y, rs1800562; H63D, rs1799945) is worth noting: for GG individuals who also carry HFE mutations, any tendency toward higher hepcidin from reduced TMPRSS6 activity could provide a modest counterbalance to the hepcidin-suppressing effect of HFE mutations.

Fibrinogen is the central protein of blood clot formation. When a vessel is damaged, thrombin cleaves fibrinogen into fibrin monomers that spontaneously polymerize into a mesh-like scaffold, which factor XIIIa then cross-links into a stable clot. The fibrinogen gamma chain (FGG)¹¹ fibrinogen gamma chain (FGG)
encoded by the FGG gene on chromosome 4q32; the gamma chain forms the outer D-domain of fibrinogen, which mediates the polymerization contacts between fibrin monomers plays a critical structural role in this process. rs6063 introduces an arginine in place of glycine at position 191 of the gamma chain — a change with measurable consequences for how fibrin clots form.

The Mechanism

The p.Gly191Arg substitution replaces a small, electrically neutral amino acid with a large, positively charged one in a region of the gamma chain involved in fibrin monomer-to-monomer contacts. This class of structural defect can disrupt the 'B:b' polymerization knob-hole interactions that drive fibrin assembly, resulting in abnormally structured clots²² This class of structural defect can disrupt the 'B:b' polymerization knob-hole interactions that drive fibrin assembly, resulting in abnormally structured clots
In dysfibrinogenemias caused by gamma-chain missense variants, the polymerization defect typically produces clots that are denser, have thinner fibers, and are more resistant to fibrinolytic breakdown compared to normal fibrin. Structurally abnormal fibrin clots are harder for plasmin to dissolve, shifting the hemostatic balance toward thrombosis.

ClinVar classifies the rs6063 T allele as pathogenic for Fibrinogen Milano XII in a digenic context — meaning this variant can act in concert with a second fibrinogen mutation to produce a named congenital fibrinopathy. In the heterozygous state (one T allele, one C allele), the abnormal gamma chain is incorporated into some fraction of circulating fibrinogen molecules, producing a quantitative but not complete disruption of normal fibrin assembly.

The Evidence

A prospective population-based cohort study (the Malmö Thrombophilia Study) genotyped common missense variants in fibrinogen genes in 1,465 VTE patients followed for approximately 10 years and 429 healthy controls³³ A prospective population-based cohort study (the Malmö Thrombophilia Study) genotyped common missense variants in fibrinogen genes in 1,465 VTE patients followed for approximately 10 years and 429 healthy controls
Memon AA, Zöller B, Svensson PJ, Sundquist J, Sundquist K. Fibrinogen genotypes and their impact on recurrence of VTE and family history. Br J Haematol. 2025;206(2):657-665.. rs6063 was significantly associated with primary VTE: OR 8.2 (95% CI 1.05–63.6) after adjustment for age and sex. The wide confidence interval reflects the rarity of the T allele (~0.5% globally) and the resulting small number of T carriers in even large cohorts — but the direction of effect is clear and statistically significant.

A 2024 multicenter analysis of 166 congenital fibrinogen disorder patients across 16 countries documented the clinical heterogeneity of dysfibrinogenemia⁴⁴ A 2024 multicenter analysis of 166 congenital fibrinogen disorder patients across 16 countries documented the clinical heterogeneity of dysfibrinogenemia
Mohsenian et al. found VTE rates around 10–11% across fibrinogen disorder subtypes, with striking obstetric impact in dysfibrinogenemic women (86% spontaneous abortion rate in affected pregnancies). FGG variants account for a meaningful proportion of dysfibrinogenemia cases.

Compound fibrinogen genotypes — where an index mutation interacts with common SNPs in the same or different fibrinogen genes — can amplify thrombogenic risk⁵⁵ Compound fibrinogen genotypes — where an index mutation interacts with common SNPs in the same or different fibrinogen genes — can amplify thrombogenic risk
Bor et al. 2022 demonstrated that fibrin structural measures (fiber thickness, mass-to-length ratios) explain thrombotic phenotype variation that neither the index mutation alone nor SNPs alone predict. This is consistent with the ClinVar digenic classification of Fibrinogen Milano XII: the pathogenic phenotype requires rs6063 together with a second fibrinogen-gene variant.

Evidence level is moderate: a large prospective cohort demonstrating a significant association (OR 8.2), supported by consistent mechanistic understanding of dysfibrinogenemia, but limited to a single primary study specifically addressing this rsID with a wide confidence interval due to variant rarity.

Practical Actions

T allele carriers — virtually all of whom are heterozygous CT — have elevated VTE risk and should be aware of high-risk situations: prolonged immobility (long flights, hospitalization), surgery, oral contraceptives or hormone replacement therapy, pregnancy, and dehydration. Anticoagulation decisions require clinical evaluation by a hematologist or thrombosis specialist; anticoagulation after a first unprovoked VTE is typically extended if a thrombophilic variant is confirmed.

The raw OR of 8.2 should be understood in context: the baseline lifetime VTE risk is roughly 5–8% in the general population, so elevated relative risk remains rare in absolute terms. Thrombotic risk is also modified by concurrent thrombophilic variants (Factor V Leiden, prothrombin G20210A), lifestyle factors, and body weight.

Interactions

rs6063 has been classified as pathogenic for Fibrinogen Milano XII in a digenic context — meaning a second fibrinogen-gene variant (in trans) is required for the full named phenotype. The Memon et al. 2025 study also examined rs6050 (FGA Thr312Ala) and rs2066865 (FGG 3' downstream), which may interact with rs6063 to amplify overall fibrinogen dysfunction and VTE risk.

Concurrent Factor V Leiden (rs6025) or prothrombin G20210A (rs1799963) would compound thrombotic risk substantially — the intersection of a dysfibrinogenemia variant and an established thrombophilia warrants hematology evaluation rather than routine monitoring.

The low-density lipoprotein receptor (LDLR) is the primary gateway through which your liver removes cholesterol from the bloodstream. Mutations in this gene cause the majority of familial hypercholesterolemia cases¹¹ Mutations in this gene cause the majority of familial hypercholesterolemia cases
LDLR mutations account for 80-85% of FH, a condition causing severely elevated LDL from birth, leading to premature cardiovascular disease. While pathogenic LDLR mutations are rare, the common variant rs6511720 in intron 1 represents a subtler regulatory change that affects how efficiently the gene is expressed. This variant was identified in genome-wide association studies as a significant modulator of LDL cholesterol levels²² identified in genome-wide association studies as a significant modulator of LDL cholesterol levels
Beta = -0.22 for LDL-C, p = 3.85 × 10⁻²⁶² in the Global Lipids Genetics Consortium meta-analysis of 170,607 individuals and coronary heart disease risk.

The T allele at rs6511720 is present in approximately 11% of people of European descent, 13% of those of African descent, but only 1% of East Asians³³ 11% of people of European descent, 13% of those of African descent, but only 1% of East Asians
Population frequency data from dbSNP and gnomAD, making this a moderately common protective variant with substantial ethnic variation. Each copy of the T allele is associated with lower LDL cholesterol levels and reduced risk of coronary heart disease.

The Mechanism

The rs6511720 variant sits within intron 1 of the LDLR gene, 2,015 bases downstream of exon 1⁴⁴ intron 1 of the LDLR gene, 2,015 bases downstream of exon 1
HGVS nomenclature: c.67+2015G>T, in a region that functions as a regulatory enhancer. The T allele creates a binding site for serum response element (SRE) transcription factors⁵⁵ binding site for serum response element (SRE) transcription factors
Luciferase reporter assays in Huh7 hepatocellular carcinoma cells demonstrated allele-specific enhancer activity, which are proteins that amplify gene transcription in response to growth signals and sterol levels. When functional studies tested the two alleles in liver cells, the rare T allele increased LDLR promoter activity by approximately 29% compared to the common G allele.

This enhanced expression translates directly to more LDL receptor proteins on the surface of liver cells. With more receptors available, hepatocytes can capture and internalize more LDL particles from the bloodstream⁶⁶ capture and internalize more LDL particles from the bloodstream
The LDLR binds apolipoprotein B-100 on LDL particles, triggering receptor-mediated endocytosis, lowering circulating cholesterol levels. The effect is subtle but meaningful: each T allele reduces LDL cholesterol by roughly 4-5 mg/dL on average.

The variant is in complete linkage disequilibrium with three other intron-1 SNPs⁷⁷ complete linkage disequilibrium with three other intron-1 SNPs
Including rs57217136, rs141787760, and rs60173709, which together form a haplotype, meaning these variants are inherited as a unit. The haplotype's combined effect on LDLR expression is approximately 29%, with each variant contributing through distinct transcription factor binding sites.

The Evidence

The association between rs6511720 and LDL cholesterol has been replicated across multiple large genetic consortia⁸⁸ replicated across multiple large genetic consortia
Including the Global Lipids Genetics Consortium (N=170,607) and validated in multiethnic cohorts, establishing this as one of the well-characterized lipid-associated variants. The T allele is associated with lower LDL-C levels (beta = -0.22 standard deviations) and correspondingly lower risk of coronary heart disease (odds ratio approximately 0.89, representing about 12% reduced risk per T allele).

Beyond baseline cholesterol levels, rs6511720 also affects response to statin therapy⁹⁹ response to statin therapy
In the JUPITER trial of rosuvastatin, rs6511720 was associated with 2.6% greater LDL-C reduction per T allele (p=0.005). This makes pharmacogenomic sense: statins work by inhibiting cholesterol synthesis in the liver, which triggers compensatory upregulation of LDLR expression. Individuals who start with genetically higher LDLR expression (T carriers) may achieve greater absolute reductions when statins further amplify receptor levels.

The functional mechanism was confirmed through luciferase reporter assays demonstrating the T allele's 29% increase in LDLR transcription¹⁰¹⁰ luciferase reporter assays demonstrating the T allele's 29% increase in LDLR transcription
Huh7 cells transfected with T allele constructs showed significantly higher promoter activity, and electrophoretic mobility shift assays proved that the T allele specifically binds serum response element (SRE) transcription factors. These experiments bridge the gap between genetic association and biological mechanism.

Interestingly, another common LDLR variant, rs688 in exon 12, interacts with rs5925 to regulate LDLR splicing efficiency¹¹¹¹ rs688 in exon 12, interacts with rs5925 to regulate LDLR splicing efficiency
The four possible haplotypes show splicing efficiencies ranging from 68.5% to 79.6%, affecting the proportion of functional LDLR transcripts. While rs6511720 modulates transcription, rs688 affects post-transcriptional processing, illustrating how multiple regulatory layers fine-tune LDLR expression.

Practical Implications

For individuals with the common GG genotype, standard cardiovascular prevention guidelines apply. Current recommendations emphasize LDL cholesterol targets based on cardiovascular risk¹²¹² Current recommendations emphasize LDL cholesterol targets based on cardiovascular risk
For general prevention, LDL <100 mg/dL; for high-risk patients with established disease, <70 mg/dL; for very high-risk patients, <55 mg/dL. Diet, exercise, and when indicated, statin therapy, remain the cornerstones of cholesterol management.

Those carrying one or two T alleles have a genetic advantage in cholesterol clearance, but this doesn't negate the importance of healthy habits. Dietary interventions can powerfully modulate LDL levels regardless of genetics¹³¹³ Dietary interventions can powerfully modulate LDL levels regardless of genetics
Soluble fiber (5-10 g/day) reduces LDL by 5-10%, plant sterols (2 g/day) by 5-15%. The Mediterranean dietary pattern, rich in vegetables, fruits, whole grains, legumes, nuts, fish, and olive oil¹⁴¹⁴ Mediterranean dietary pattern, rich in vegetables, fruits, whole grains, legumes, nuts, fish, and olive oil
Multiple studies demonstrate LDL reductions of 8-15% with adherence to Mediterranean diet, has been consistently shown to reduce cardiovascular events independent of baseline cholesterol levels.

If statin therapy is prescribed, T allele carriers may achieve target cholesterol levels with lower doses or see greater absolute reductions at standard doses. However, dose adjustments should always be made based on measured lipid responses rather than genetic prediction alone. Guidelines recommend checking lipid panels 4-12 weeks after starting or adjusting statin therapy¹⁵¹⁵ Guidelines recommend checking lipid panels 4-12 weeks after starting or adjusting statin therapy
Repeated every 3-12 months to assess adherence and response, with dosing titrated to achieve individual risk-based targets.

Interactions

The rs6511720 variant is in complete linkage disequilibrium with rs57217136, rs141787760, and rs60173709¹⁶¹⁶ complete linkage disequilibrium with rs57217136, rs141787760, and rs60173709
These four intron-1 variants form a haplotype with combined effects on LDLR expression, meaning they are inherited together. The protective T allele at rs6511720 virtually always occurs with the minor alleles at these linked positions, and their combined regulatory effects produce the observed 29% increase in LDLR expression.

Beyond the LDLR locus, cholesterol metabolism involves a network of genes. PCSK9 (proprotein convertase subtilisin/kexin type 9) negatively regulates LDLR by promoting receptor degradation¹⁷¹⁷ PCSK9 (proprotein convertase subtilisin/kexin type 9) negatively regulates LDLR by promoting receptor degradation
Loss-of-function PCSK9 variants like rs11591147 increase LDL receptor levels and reduce cardiovascular risk. Conversely, gain-of-function PCSK9 variants like rs505151 accelerate LDLR degradation and raise cholesterol. Individuals carrying both protective LDLR variants (like rs6511720 T) and protective PCSK9 variants would experience compounded benefits, while those with risk alleles at both loci might face elevated cholesterol from dual mechanisms.

The rs688 variant in LDLR exon 12 affects splicing efficiency when paired with rs5925¹⁸¹⁸ rs688 variant in LDLR exon 12 affects splicing efficiency when paired with rs5925
The combined haplotype influences what proportion of LDLR transcripts are properly processed. Someone carrying the rs6511720 T allele (high transcription) but also the rs688 T allele (reduced splicing) might see attenuated benefits, as more transcripts are produced but fewer are successfully spliced into functional protein. Conversely, optimal LDLR function would result from combining high transcription (rs6511720 T) with efficient splicing (rs688 C, rs5925 C).

APOB variants affect the ligand that LDLR recognizes¹⁹¹⁹ APOB variants affect the ligand that LDLR recognizes
Rare pathogenic APOB mutations cause familial hypercholesterolemia through defective receptor binding, while common APOB polymorphisms modulate cholesterol levels through effects on LDL particle composition. The ultimate cholesterol outcome reflects the interplay between hepatic LDLR expression (affected by rs6511720), receptor degradation (PCSK9), and ligand quality (APOB).